Life sciences span a wide range of disciplines that study living organisms in six categories, from molecules and cells to ecosystems and human health. The category that intersects in our world is Applied Life Sciences. And more specifically these fields that translate biological knowledge into practical solutions.
- Biotechnology – using living systems for technology and innovation
- Pharmacology – drug action and development
- Biomedical Science – disease mechanisms, diagnostics, therapeutics
- Stem Cell Biology & Regenerative Medicine – cell-based therapies
In this monthly report you will find news and highlights in the Applied Life Science.
Biotechnology
FDA Launches Framework for Accelerating Development of Individualized Therapies for Ultra-Rare Diseases
The U.S. Food and Drug Administration (FDA) issued draft guidance for sponsors seeking full approval for targeted individualized therapies by generating substantial evidence of effectiveness and safety when randomized controlled trials are not feasible due to small patient populations.
Neurizon Initiates Dosing of NUZ-001 in HEALEY ALS Platform
Neurizon® Therapeutics Limited, a clinical-stage biotechnology company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce that the first participant has been dosed in Regimen I of the HEALEY ALS Platform Trial evaluating Neurizon’s lead candidate, NUZ-001, for the treatment of amyotrophic lateral sclerosis (ALS).
Pharmacology
Ibex Medical Analytics Accelerates Global Momentum in AI-Powered Pathology with Strategic Leadership Transition and Expansion in Biopharma
Ibex Medical Analytics (Ibex), the global leader in clinical-grade AI-powered pathology, announced continued commercial momentum and expanding global adoption alongside a leadership transition designed to accelerate the company’s next phase of growth. Effective immediately, Yair Heller, formerly Chief Operating Officer, has been appointed Chief Executive Officer, and co-founder Joseph Mossel will lead Ibex’s rapidly expanding biopharma division and U.S. clinical growth initiatives.
Certara Expands Simcyp® Simulator to Streamline Regulatory Submissions and Internal Efficiencies
Certara, Inc., a global leader in model-informed drug development, announced the release of the Simcyp® Simulator Version 25, the latest update to its industry-leading physiologically-based pharmacokinetic (PBPK) modeling platform.
Dose of Reality: Health Affairs Scholar Analysis Finds Big Pharma’s Patent Abuse Growing in Scale, Keeping Prescription Drug Prices High
In case you missed it, an analysis authored by researchers affiliated with the University of Alabama School of Law and published in Health Affairs Scholar, highlights how Big Pharma continues to game the U.S. patent system to block competition from more affordable alternatives, enabling brand name drug manufacturers to maintain monopolies over their biggest money-makers and keep prices high.
Model N Expands into Global Market Access Through Strategic Partnership with CCX
Model N, an end-to-end commercialization, revenue optimization, and compliance platform for life sciences companies, announced a strategic partnership with CCX, a market leading technology company focused on accelerating global market access and pricing strategy. The partnership extends Model N’s platform functionality into earlier phases of the drug lifecycle and expands the company’s capabilities beyond pricing and market access operations into global launch pricing strategy. As a result, joint customers can more effectively coordinate pricing strategies and ensure timely launch execution in an increasingly complex regulatory and market access environment.
Coriolis Pharma US Inc. Launches Operations in North Carolina
Coriolis Pharma celebrates the grand opening of its new U.S. headquarter and laboratory, marking the start of operations at the Alexandria Center for Advanced Technologies (ACAT) in North Carolina’s Research Triangle Park (RTP). This expansion enables Coriolis to provide its North American clients with direct access to specialized expertise in formulation and drug product development as well as analytical characterization of biopharmaceutical products.
LEON and Harro Höfliger Announce Strategic Collaboration for Global Distribution and After-Sales Service of Nanoencapsulation Equipment
leon-nanodrugs GmbH (LEON), a developer of advanced nanoencapsulation technology and equipment, and Harro Höfliger, a global expert in pharmaceutical engineering and GMP-compliant production, announced a strategic collaboration to expand worldwide access to LEON’s FR-JET® technology and portfolio of equipment. Under the agreement, Harro Höfliger becomes a non-exclusive global authorized commercialization and service partner for LEON’s products.
ProBioGen Introduces CMC Navigator™ to Help Biopharma Teams Select the Best CMC Path Forward
ProBioGen introduces CMC Navigator™, a set of four clearly defined CMC service models designed to support biopharmaceutical companies across all key stages of protein Chemistry, Manufacturing and Controls (CMC) development. Each model addresses a distinct development or program need, helping teams navigate flexible CMC strategies and align scope, timelines, and execution with current priorities, ultimately adding value as programs move forward.
BioMed X Advances Women’s Health Innovation at Inaugural XFem Labs Pitch & Connect Event
BioMed X, an innovation hub for pharma headquartered in Heidelberg, hosted the first XFem Labs Pitch & Connect event on February 13th in Heidelberg, marking the official launch of XFem Labs, its new Women’s Health R&D Accelerator established with support from the Gates Foundation. The purpose of this initiative is to build a world-class women’s health innovation hub in Heidelberg that advances early-stage research into scalable solutions for women in need around the world, including low- and middle-income countries.
Big Pharma Earnings Watch: Amgen and Bristol Myers Squibb
Recently Amgen and Bristol Myers Squibb reported better-than-expected fourth quarter earnings, following price increases the Big Pharma giants imposed on brand name products at the start of the year. In January, both companies raised prices on dozens of brand name medicines, with Amgen increasing prices on 21 prescription drugs and Bristol Myers Squibb increasing prices on nine prescription drugs. The latest results underscore how major pharmaceutical manufacturers continue to bank big profit and revenue growth while hiking drug prices – often at rates outpacing inflation.
MedTech and Medical Devices
BioLargo Subsidiary Clyra Medical Technologies Secures First Stocking Order with Advanced Solution for ViaCLYR(TM) Wound Irrigation Solution
BioLargo, Inc., a cleantech and life sciences innovator, announced that its subsidiary, Clyra Medical Technologies, Inc., has received its first commercial stocking order from Advanced Solution, LLC for ViaCLYR™, Clyra’s FDA-cleared wound irrigation solution. The order marks the start of commercial distribution and represents Clyra’s transition from development-stage operations to early revenue generation.
BIOTRONIK Receives FDA Approval for Solia CSP S, World’s First Pacing Lead Specifically Designed For LBBAP
BIOTRONIK, a global leader in cardiovascular medical technology, announced its Solia CSP S pacing lead has received approval from the U.S. Food and Drug Administration (FDA). With this approval, Solia CSP S is now commercially available in the United States, expanding access to a dedicated solution for Left Bundle Branch Area Pacing (LBBAP).
Clinical Studies and Trials
Randomized Controlled Trial Demonstrated Positive Outcomes for FDA-Cleared Brain-Computer Interface IpsiHand® System in Chronic Stroke Rehabilitation
Kandu, Inc., a healthcare technology company developing brain-computer interface (BCI)–enabled solutions for post-stroke recovery, announced results from the first randomized controlled trial evaluating an FDA-cleared, non-invasive BCI therapy in chronic stroke survivors. The findings, presented at the International Stroke Conference (ISC) 2026 on February 6 in New Orleans, showed that patients using the IpsiHand System achieved significantly greater improvements in upper extremity motor function than those participating in a home exercise program, with a number needed to treat (NNT) of 2.2 for one patient to achieve a clinically meaningful functional benefit.
Bioxytran, Inc. Reports Positive Phase 1b/2a Clinical Study Results for ProLectin-M, a Broad-Range Antiviral Drug in Mild to Moderate COVID-19
Bioxytran, Inc., a clinical-stage biotechnology company developing carbohydrate-based therapeutics, announced results from a randomized, double-blind, placebo-controlled Phase 1b/2a clinical study evaluating oral ProLectin-M in hospitalized patients with mild to moderate COVID-19 caused by SARS-CoV-2.
Devonian Reports Human Liver-on-a-Chip Data Demonstrating Disease-Relevant Modulation of MASH by Thykamine™, with Dose-Dependent Anti-Fibrotic and Anti-Inflammatory Effects
Devonian Health Group Inc. announced positive results from a follow-up preclinical study evaluating Thykamine™ in a human metabolic-associated steatohepatitis (MASH) model using PhysioMimix® Liver-on-a-Chip platform. The study was conducted by CN Bio Innovations, Cambridge, UK.
Funding and Acquisitions
Supreme Group Expands Science-First Creative with Broth
Supreme Group, a marketing and communications platform for healthcare and life sciences, announced the acquisition of Broth, a science-first creative agency that brings insight and precision to the most critical moments in healthcare commercialization.
LEON closes oversubscribed financing to drive global LNP manufacturing scale-up
leon-nanodrugs GmbH (LEON) announced he successful closing of a financing round, with participation from both existing and new investors. The round was significantly oversubscribed, underscoring strong investor conviction in LEON’s proprietary technology, commercial readiness, and accelerating global demand for scalable nanoparticle manufacturing solutions.
Vygon acquires Stiletto® and its SlipStream™ technology from Avia Vascular
Vygon, a group specialized in the design, manufacturing and marketing of medical devices in neonatology and vascular management clinical specialties, announces its acquisition of Stiletto®, a new generation of extended‑dwell catheters integrating SlipStream™ technology, from Avia Vascular (Salt Lake City – UT). This strategic acquisition enhances Vygon’s leadership in vascular access and supports its ambition to accelerate growth in the United States, where extended-dwell catheters represent a significant and rapidly expanding segment of the market. Financial details were not disclosed.
CubaseBio Emerges from Stealth to Scale True 3D Spatial Transcriptomics with €5.9M in Financing
CubaseBio, a biotechnology company founded by pioneers in spatial biology, announced it has secured €5.9 million in blended financing. The funding comprises a €2 million non-dilutive grant from the European Innovation Council (EIC) Transition program and €3.9 million in private capital and convertibles from Voima Ventures, Nordic Science Investments (NSI), Illumina Ventures, Almi invest, Life Science Invest and several undisclosed private investors from the genomics technology space. Voima and NSI, two Nordic-based deeptech and life science investors, served as the lead investors.
Events
AMCP2026
When: April 13-16, 2026
Where: Nashville, TN
Event Page
Hashtag: #AMCP2026
Register for this event.
Shaping what’s next in Managed Care Pharmacy!
Join 4,000+ managed care pharmacy professionals at AMCP 2026 in Nashville, TN on April 13-16! Explore cutting-edge education, earn CE credits, attend the Al pre-conference, real-world evidence, precision medicine and other emerging health care trends. Network with health care decision-makers from health plans, PBMs, pharmaceutical companies, and more.
Bio-IT World Conference & Expo
When: May 19-21, 2026
Where: Boston, MA
Event Page
Hashtag: #BioITExpo
Register for this event.
The Bio-IT World Conference & Expo is the premier global event showcasing technologies and analytic approaches that solve problems, accelerate science, and drive the future of precision medicine. Now in its 25th year, the event convenes more than 2,900 leaders from biopharma, clinical research, healthcare, informatics, and technology to exchange ideas, showcase solutions, and spark collaborations that push the boundaries of biomedical research, drug discovery, and patient outcomes. Spanning 200+ sessions—including plenary keynotes, symposia, technical workshops, and hands-on demonstrations—Bio-IT World offers unmatched opportunities to explore the tools, platforms, and strategies redefining R&D and clinical care. From AI, generative AI, and machine learning to multimodal and real-world data strategies, FAIR/Open Source practices, pilot programs, new product launches, and biotech investment trends, attendees engage in transformative conversations that translate innovation into measurable value.
BIO International Convention
When: June 22-25, 2026
Where: San Diego, CA
Event Page
Register for this event.
Touted as the largest and most comprehensive event for biotechnology, the BIO International Convention includes the full ecosystem of biotech. Organizers explain that it is the place to reconnect with your “why”—or the place where you remember your goal is to improve lives. It also fosters building relationships and making connections through their proprietary BIO Partnering meeting-scheduling platform, which is available with the Premier Access registrations.
